Health & Fitness
Health and Fitness
Health and Fitness
Wed, February 25, 2009 Adipose-Derived Stem and Regenerative Cells Prevent Mortality and Reduce Kidney Damage in Preclinical Study
SAN DIEGO--([ BUSINESS WIRE ])--Cytori Therapeutics, Inc. (NASDAQ: CYTX) finds adipose tissue-derived stem and regenerative cells (ADRCs) significantly reduce mortality and improve renal function in an acute kidney injury model. The preclinical results were reported today at the 14th Annual International Conference on Continuous Renal Replacement Therapies.
Acute kidney injury is a tremendous medical and financial burden to the healthcare system due to high mortality rates and the lack of effective therapies beyond supportive treatments. However, these new study findings by Cytori may lead to new therapeutic treatments using ADRCs that could reduce morbidity and mortality associated with acute kidney injury. Although this study was performed using a manual extraction technique, this potential application could be made more efficient and cost effective with the use of Cytori's Celution® System to isolate clinical grade ADRCs in real time.
As part of the study design, acute kidney injury was induced in 29 preclinical research subjects by occluding blood flow into and out of both kidneys for 38 minutes. Twenty minutes after reperfusion of the kidneys, ADRCs or saline only were injected intra-arterially. All subjects were assessed daily for 7 days for markers of kidney function (serum creatinine and blood urea nitrogen) and survival.
After seven days, 100% of ADRC-treated preclinical subjects survived compared to only 57% in the control group (p<0.01). The ADRC-treated subjects also showed statistically significant improvements in kidney function, as measured by serum creatinine (p<0.0001) and blood urea nitrogen levels (p<0.0001). In addition, substantial improvement in the histologic structure within the kidney was observed, as measured by a reduction in tubular cell death and epithelial shedding (p<0.0001). This study suggests that ADRCs significantly accelerate renal repair and preserve renal function, offering a potential therapeutic approach in renal reparative medicine.
Kidney disease represents an annual cost of greater than $32 billion. More than 300,000 Americans are diagnosed with acute kidney injury annually, facing prolonged hospitalization, marked increases in morbidity as well as mortality.
About Cytori
Cytori's (NASDAQ: [ CYTX ]) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution(R) 800 System is being introduced in Europe into the reconstructive surgery market while the Celution(R) 900 System is being commercialized globally for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. [ www.cytoritx.com ]
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange
